FDA warned onlineotcmeds.com for selling unapproved, misbranded opioids, benzodiazepines, and Schedule II stimulants to U.S. consumers online.
What happened
FDA reviewed the website onlineotcmeds.com and found it offering prescription opioids, benzodiazepines, and Schedule II stimulants for sale to U.S. consumers without a prescription. FDA says the site marketed these as drugs for human use but had no FDA-approved applications for them. FDA also says the labeling lacked adequate directions for use, making them misbranded.
What FDA found
FDA says the website offered opioids, benzodiazepines, and Schedule II stimulants that are unapproved new drugs because no FDA-approved applications are in effect for them.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]FDA says the drugs are misbranded because their labeling does not give adequate directions for use by a layperson.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]FDA says the website offered prescription drugs for sale without a prescription.
FD&C Act sections 503(b)(1) and 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]
What FDA wants
FDA asks onlineotcmeds.com to stop offering any unapproved and misbranded drugs to U.S. consumers. It asks the company to reply in writing within 15 working days with the steps taken to correct the violations and prevent recurrence.
Who should pay attention
- online pharmacies selling prescription drugs
- platforms that host or link to pharmacy websites
- brands whose prescription drug names are used by rogue sellers
This is a summary. Read the original letter on fda.gov.